GHRH
Growth hormone-releasing hormone, the hypothalamic peptide that triggers GH release.
Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide that stimulates the anterior pituitary to release growth hormone (GH). Synthetic GHRH analogues — including tesamorelin (an FDA-approved 44-amino-acid analogue), CJC-1295, and sermorelin — are research subjects in lipodystrophy, visceral fat reduction, and the GH/IGF-1 axis. They differ from direct GH administration in that they preserve the body's pulsatile GH release pattern and the negative-feedback loop, which is why they are often investigated as more 'physiological' than recombinant GH.
- GlossaryIGF-1
Insulin-like growth factor 1 — the main downstream mediator of growth hormone effects.
- GlossaryGHS receptor (GHSR-1a)
The growth-hormone secretagogue receptor — also called the ghrelin receptor.
- GlossaryGRF (1-29)
The biologically active 29-amino-acid N-terminal fragment of growth hormone-releasing hormone.
- ResearchCJC-1295 with DAC 5 mg
CJC-1295 with Drug Affinity Complex (DAC) — an extended GHRH analogue designed for half-life extension through covalent albumin binding.
- ResearchCJC-1295 no DAC 10 mg
CJC-1295 without DAC — short-acting modified GRF(1-29). Commonly used in preclinical GH-pulse research alongside ipamorelin.